BMS 690514

Drug Profile

BMS 690514

Alternative Names: BMS-690514

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Non-small cell lung cancer

Most Recent Events

  • 26 Oct 2011 Safety and pharmacokinetic data from two phase I trials in healthy volunteers released Bristol-Myers Squibb ,
  • 26 Oct 2011 Bristol-Myers Squibb completes a phase I pharmacokinetic trial in healthy volunteers in Switzerland
  • 18 Jul 2011 Bristol-Myers Squibb completes a phase II trial for Non-small cell lung cancer (second-line therapy or greater) in Japan (NCT01167244)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top